logo BDSP

Base documentaire

  1. Over a decade of experience with a yeast recombinant hepatitis B vaccine.

    Article - En anglais

    Experience with the yeast recombinant hepatitis B vaccine Engerix-B now exceeds 10 years.

    We reviewed published studies on this vaccine.

    These show the vaccine to be safe, causing mostly only minor local symptoms and to be highly immunogenic both in monitored clinical trials and under field conditions.

    Engerix-B consistently elicits high geometric mean antibody titres and a high protective efficacy has been established in three groups at high-risk of hepatitis B infection, homosexual men, institutionalised mentally handicapped subjects and neonates of chronic carrier mothers.

    The profile of the recombinant hepatitis B vaccine in certain high-risk groups and immuno compromised people is discussed.

    Finally we present updated post marketing surveillance data based on 496 million distributed doses of vaccine.

    Mots-clés Pascal : Homme, Virus hépatite B, Orthohepadnavirus, Hepadnaviridae, Virus, Vaccin, Etude longitudinale, Evaluation performance, Immunogénicité, Immunoprotection, Toxicité, Pharmacovigilance, Article synthèse, Engerix B

    Mots-clés Pascal anglais : Human, Hepatitis B virus, Orthohepadnavirus, Hepadnaviridae, Virus, Vaccine, Follow up study, Performance evaluation, Immunogenicity, Immunoprotection, Toxicity, Pharmacovigilance, Review

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0489325

    Code Inist : 002B05A02. Création : 22/03/2000.